Drug Profile
Somatropin - Altus Pharmaceuticals
Alternative Names: ALTU-238; Extended-release somatropin - Altus; hGH - AltusLatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator Altus Pharmaceuticals
- Class Growth hormones; Hormonal replacements; Obesity therapies; Recombinant proteins
- Mechanism of Action Human growth hormone replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Somatotropin deficiency
Most Recent Events
- 12 Nov 2012 Althea Technologies acquires the assets and IP portfolio of Altus Pharmaceuticals
- 10 Jun 2009 Adverse events and pharmacokinetics data from a phase Ic trial in healthy adult volunteers presented at the 91st Annual Meeting of the Endocrine Society (ENDO-2009) ,
- 09 Jan 2009 Altus Pharmaceuticals completes a phase Ic trial in healthy subjects in USA